Navigation Links
Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology
Date:12/7/2008

--Complete Remissions Achieved with Voreloxin in Poor Risk Frontline Elderly AML and in Combination with Cytarabine in Relapsed/Refractory AML-

--Conference Call Scheduled for Tuesday, December 9 at 11:00 am ET to Discuss Phase 2 Study Results in AML--

SAN FRANCISCO, Dec. 7 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the presentation of new data from two ongoing clinical trials demonstrating that the company's novel drug candidate, voreloxin, shows promising safety and efficacy results both in patients with newly diagnosed and relapsed/refractory acute myeloid leukemia (AML). These data were presented today at two poster sessions at the 50th Annual Meeting of the American Society of Hematology in San Francisco. The presentations are highlighted below.

Phase 2 Study of Voreloxin as Single Agent Therapy (REVEAL-1 Trial)

Interim data from the REVEAL-1 (Response Evaluation of VorEloxin in AmL) single agent Phase 2 trial show that voreloxin induces complete remissions in poor risk frontline elderly AML patients who are unlikely to benefit from standard induction chemotherapy. Many older AML patients cannot tolerate or do not respond well to standard induction chemotherapy. In Schedule A, 29 patients with a median age of 75 were enrolled and treated with 72 mg/m(2) of voreloxin weekly for three weeks. Eleven patients achieved a complete remission (CR) or complete remission without full platelet recovery (CRp) for an overall remission rate of 38 percent. An additional 5 patients had bone marrow blast reductions to less than 5 percent. The median duration of response for patients achieving a CR or CRp has not been reached.

Grade 3 or higher non-hematologic adverse event
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH
2. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
3. SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases
4. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
5. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
6. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
7. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
8. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
9. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
10. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
11. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014  Seventy-one percent of Americans ... OxyContin is a serious public health and safety issue in ... from a survey released today by Repass & Partners, a ... "Americans understand the severity of the prescription medication ... progress with this very serious health situation facing our country," ...
(Date:8/21/2014)... August 21, 2014 BreedIT ... Ltd., the exclusive worldwide license holder and distributor ... breeders and researchers, today is pleased to announce ... with Seach Ltd, a leading Israeli medical Cannabis ... and develop new breeds of medical Cannabis to ...
(Date:8/21/2014)... -- Henry Schein, Inc. (NASDAQ: HSIC ), the world,s ... dental, animal health and medical practitioners, announced today that the ... , September 4, 2014 – Baird 2014 Healthcare Conference ... ET , September 8, 2014 – Morgan ... , NY at 1:25 p.m. ET Henry Schein,s ...
Breaking Medicine Technology:Consumers Desperate For Measures To Curb Prescription Drug Abuse 2Consumers Desperate For Measures To Curb Prescription Drug Abuse 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 4Henry Schein To Present At Two Investor Conferences In September 2
... Australia, May 4 /PRNewswire-Asia-FirstCall/ -- Pharmaceutical,company Pharmaxis (ASX: PXS; ... positive,results of its recently completed international Phase III trial ... represents one of,the largest clinical trials conducted in cystic ... of the trial was to assess whether Bronchitol,improves lung ...
... Va., May 1 C. Larry Pope, President and ... SFD ), sent the following update to all ... at its joint venture operation in Veracruz:To Our Employees:The ... on a minute-to-minute basis, and while we would like ...
Cached Medicine Technology:Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial 2Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial 3Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial 4Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial 5Smithfield Sends Update to Employees on Testing Process at Veracruz Joint Venture 2
(Date:8/23/2014)... (PRWEB) August 23, 2014 Cardiomyopathy ... the function of the myocardium (the heart muscle) ... common symptoms are dyspnea (breathlessness) and peripheral edema ... often at risk of dangerous forms of irregular ... common form of cardiomyopathy is dilated cardiomyopathy. , ...
(Date:8/23/2014)... 2014 Peripheral intervention surgeries are part ... etc, thereby addressing the root cause of peripheral artery ... to the other part of the arteries where the ... procedures require the use of a catheter, (which is ... these catheters are inserted through a thin cut in ...
(Date:8/23/2014)... New York (PRWEB) August 23, 2014 ... ) filed on behalf of individuals who ... Conserve hip replacement line continue to move forward ... Georgia, Bernstein Liebhard LLP reports. According to an ... a bellwether trial program that would allow the ...
(Date:8/23/2014)... 23, 2014 Professional kitchen employees, prospective ... aid in preparing for Food Safety Certification exams thanks ... by Dynamic Path. , Dynamic Path announced the release ... more than 200 review questions for culinary industry students ... to cover requirements of the ServSafe® Food Safety Certification, ...
(Date:8/23/2014)... Teen drug and alcohol abuse is a major ... NC. Substance abuse can happen to people of all ... alcohol dependency in higher numbers than ever before. ... but don’t know where to find professional youth rehab. ... challenge because most treatment options are designed for adults. ...
Breaking Medicine News(10 mins):Health News:Cardiomyopathy (Heart Muscle Disease) Therapeutics Clinical Trials Market 2014 Analysis in a New Report Available at MarketOptimizer.org 2Health News:Cardiomyopathy (Heart Muscle Disease) Therapeutics Clinical Trials Market 2014 Analysis in a New Report Available at MarketOptimizer.org 3Health News:Cardiomyopathy (Heart Muscle Disease) Therapeutics Clinical Trials Market 2014 Analysis in a New Report Available at MarketOptimizer.org 4Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 2Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 3Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 4Health News:Food Handler Safety Certification Made Easy with Dynamic Path 2Health News:Troubled Teens Wilmington Helpline Guides Adolescents to the Path of Recovery 2
... recently diagnosed with diabetes and hypertension have time to ... pressure without medications, but not too much time. ... up to a year were smalla two-day reduction in ... Chicago researchers published online for the Journal of ...
... the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial ... control group of men undergoing usual care, according to a ... the National Cancer Institute. The Prostate, ... multi-center, two-arm trial, which began enrollment in November 1993 with ...
... of imaging services received by patients in a hospital, in-patient ... the Journal of the American College of Radiology . ... of the population, were without health insurance for some or ... preventive care, delays in diagnosis and unnecessary deaths. ...
... FRIDAY, Jan. 6 (HealthDay News) -- Air pollution may increase ... in black American women, a new study suggests. Previous ... acute cardiovascular events such as stroke and heart attack, but ... of chronic diseases such as diabetes and high blood pressure ...
... , FRIDAY, Jan. 6 (HealthDay News) -- If the current ... has left you searching for something else for your child ... the effects of these medications can vary widely. ... much of the drug is absorbed into the bloodstream], and ...
... documents shows that Philip Morris USA manipulated data on ... actual toxicity levels and increasing the risk of heart, ... information can,t be taken at face value, the researchers ... of additives, including menthol, should be eliminated from cigarettes ...
Cached Medicine News:Health News:For those with diabetes, controlling blood pressure is crucial, but not urgent 2Health News:For those with diabetes, controlling blood pressure is crucial, but not urgent 3Health News:Study shows no evidence of a mortality benefit to PSA screening 2Health News:Smog Tied to Raised Risk of Chronic Illness in Black Women 2Health News:ADHD Drug Shortage Pushes Parents to Seek Substitutes 2Health News:ADHD Drug Shortage Pushes Parents to Seek Substitutes 3Health News:Tobacco company misrepresented danger from cigarettes 2
... cost-effective line of compact CO2 systems available ... 30 or 40 watts combines portability ... extremely accurate laser beam, as well as ... advantageous for small operating theatres and are ...
... Applications include PhotoLightFACIAL facial skin ... vein removal. Incorporates a ... to 1200nm), multiple hand pieces ... give you the most flexibility. ...
... delivered through an ultra thin flexible 400 - ... freedom of movement when performing surgery. The ... range of handpieces. Handpieces are supplied with ... mm. Straight and angled fiber guides with ...
These are the Reusable Components (minus cannula), to be used with the VersaStep™ Plus Reposable Short System....
Medicine Products: